Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Accelerated Community Oncology Research Network Bayer |
---|---|
Information provided by: | Accelerated Community Oncology Research Network |
ClinicalTrials.gov Identifier: | NCT00779311 |
This research study is being performed at approximately 3 sites associated with Accelerated Community Oncology Research Network, Inc. (ACORN). Approximately 45 subjects will take part in this study.
In this study, everyone will receive the same dose of mFOLFOX6 and Avastin. There will be five groups of subjects. Each group of subjects will receive a higher dose of Nexavar than the previous group. This will continue until a subject group has a major side effects from the dose they are given. This is so that the sponsor can determine the highest dose of Nexavar that can be used with mFOLFOX6 and AVastin (this is called the maximum tolerated dose or MTD).
Condition | Intervention | Phase |
---|---|---|
Metastatic Colorectal Cancer |
Drug: Sorafenib |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer |
Estimated Enrollment: | 45 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimenal: Experimental
All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle.Sorafenib will be administered daily throughout treatment beginning on day 1
|
Drug: Sorafenib
Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
|
This is an investigator-initiated, multicenter, network, Phase 1, open-label, dose-ranging study. The primary objective is to determine the safety and MTD for sorafenib when used in combination with mFOLFOX6 and bevacizumab in patients with mCRC who have not received prior chemotherapy or bevacizumab.
The study will include a Screening/Baseline Phase, a Treatment Phase and a Follow-up Phase. The study will be conducted at approximately 3 Accelerated Community Oncology Research Network, Inc (ACORN) Network Sites.
The maximum sample size will be 45 patients (up to 30 patients for determining MTD at Phase I, and an additional 15 patients to provide for estimate of progression free survival). It is likely that 21-24 patients will be sufficient for establishing MTD, and that the total sample will therefore be 36-39 patients.All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle. Treatment cycle length is 2 weeks (Q2W). Sorafenib will be administered daily throughout treatment beginning on day 1. The study drug dose levels for sorafenib are shown in Table 1.Dose limiting toxicity will be defined as any grade 4 hematologic event or any grade 3 or 4 non-hematologic event occurring during cycle 1 that is attributable to sorafenib or the combination. The following events are excluded from this definition: grade 3 nausea and/or vomiting responsive to antiemetics; grade 3 fever or infection; grade 3 diarrhea responsive to antidiarrheal therapy.
Three patients will be enrolled at a dose level and observed for dose-limiting toxicities (DLTs) for 1 cycle of treatment. Dose escalation for sorafenib will depend on the number of patients experiencing DLT(s) as follows:
Dose escalation will continue until the MTD is determined or until all dose levels have been completed. The MTD is defined as the dose at which ≤1 of 6 patients experience DLT(s), and above which ≥2 of 6 patients experience DLT(s). If the MTD is at Dose Level 2 (or lower), then the study will be terminated and no further patients will be enrolled.
Once the MTD for sorafenib combined with mFOLFOX6 and bevacizumab has been determined, an additional 15 patients with mCRC will be enrolled into an extension of the Phase 1 study. These patients will be treated at the MTD for sorafenib with the combination therapy to assess PFS and safety of the regimen as first-line therapy in mCRC. All patients will be eligible for indefinite treatment in the absence of disease progression or unacceptable toxicity.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Adequate bone marrow, liver and renal function at study entry as assessed by the following:
Exclusion Criteria:
Contact: Amanda Johns, RHIA, CCRP | 901-435-5578 | ajohns@sosacorn.com |
United States, Georgia | |
Central Georgia Cancer Care | Recruiting |
Macon, Georgia, United States, 31201 | |
Principal Investigator: Fred Schnell, MD | |
United States, Montana | |
Hematology Oncology Centers of the Northern Rockies | Recruiting |
Billings, Montana, United States, 59101 | |
Principal Investigator: Troy Fiddler, MD | |
United States, Tennessee | |
The West Clinic | Recruiting |
Memphis, Tennessee, United States, 38120 | |
Principal Investigator: Lee Schwartzberg, MD |
Principal Investigator: | Fred Schnell, MD | Central Georgia Cancer Care |
Responsible Party: | Accelerated Community Oncology Research Network, Inc ( Amanda Johns, RHIA, CCRP ) |
Study ID Numbers: | AFMSMCRC0706 |
Study First Received: | October 23, 2008 |
Last Updated: | December 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00779311 |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
Metastatic Colorectal Cancer |
Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Gastrointestinal Neoplasms Bevacizumab |
Intestinal Diseases Sorafenib Rectal Diseases Intestinal Neoplasms Colorectal Neoplasms |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |